Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) Director Acquires $112,000.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) Director Mats Wahlstrom purchased 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was purchased at an average price of $2.24 per share, for a total transaction of $112,000.00. Following the acquisition, the director owned 197,555 shares of the company’s stock, valued at $442,523.20. The trade was a 33.89% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $2.45 on Thursday. The company has a debt-to-equity ratio of 47.60, a current ratio of 4.22 and a quick ratio of 3.86. TriSalus Life Sciences, Inc. has a 1-year low of $2.16 and a 1-year high of $7.95. The business has a 50-day moving average price of $3.90 and a two-hundred day moving average price of $4.26.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $12.88 million for the quarter, compared to the consensus estimate of $14.02 million. On average, equities research analysts expect that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wall Street Zen lowered shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Zacks Research raised TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Finally, Citigroup reissued a “buy” rating on shares of TriSalus Life Sciences in a research note on Tuesday, November 10th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.

Check Out Our Latest Report on TLSI

Institutional Trading of TriSalus Life Sciences

A number of large investors have recently made changes to their positions in the company. Cura Wealth Advisors LLC acquired a new position in TriSalus Life Sciences in the second quarter valued at about $36,000. New York State Common Retirement Fund bought a new stake in shares of TriSalus Life Sciences in the third quarter worth about $48,000. Russell Investments Group Ltd. bought a new stake in shares of TriSalus Life Sciences in the third quarter worth about $68,000. Virtu Financial LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth about $79,000. Finally, Provenance Wealth Advisors LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth about $94,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.

Recommended Stories

Insider Buying and Selling by Quarter for TriSalus Life Sciences (NASDAQ:TLSI)

Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.